Abstract:A comprehensive summary of recent advances in SARS‐CoV‐2 3CLpro inhibitors (including marketed drugs, peptidomimetic, and non‐peptidomimetic synthetic compounds, as well as natural compounds and their derivatives), including the inhibitory activities, inhibitory mechanisms, and key structural features, provides new insights for designing and developing more efficacious 3CLpro inhibitors as broad‐spectrum anti‐coronavirus agents. The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has demonstrated that 3CLpros play an indispensable role in viral replication and have been recognized as key targets for preventing and treating coronavirus‐caused infectious diseases, including COVID‐19. This review is focused on the structural features and biological function of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) main protease Mpro (also known as 3CLpro), as well as recent advances in discovering and developing SARS‐CoV‐2 3CLpro inhibitors. To better understand the characteristics of SARS‐CoV‐2 3CLpro inhibitors, the inhibition activities, inhibitory mechanisms, and key structural features of various 3CLpro inhibitors (including marketed drugs, peptidomimetic, and non‐peptidomimetic synthetic compounds, as well as natural compounds and their derivatives) are summarized comprehensively. Meanwhile, the challenges in this field are highlighted, while future directions for designing and developing efficacious 3CLpro inhibitors as novel anti‐coronavirus therapies are also proposed. Collectively, all information and knowledge presented here are very helpful for understanding the structural features and inhibitory mechanisms of SARS‐CoV‐2 3CLpro inhibitors, which offers new insights or inspiration to medicinal chemists for designing and developing more efficacious 3CLpro inhibitors as novel anti‐coronavirus agents.

Structural biology of SARS-CoV-1/SARS-CoV-2 main protease

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design.

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2

Structural Biology of SARS-CoV-2 Mpro and Drug Discovery.

Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease

Exploring the Efficacy of Noncovalent SARS-CoV-2 Main Protease Inhibitors: A Computational Simulation Analysis Study.

The SARS-CoV-2 main protease as drug target

The Search for A Structural Basis for Therapeutic Intervention Against the Sars Coronavirus

The Crystal Structures of Severe Acute Respiratory Syndrome Virus Main Protease and Its Complex with an Inhibitor

Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin

Crystal structures of main protease (M pro ) mutants of SARS-CoV-2 variants bound to PF-07304814

Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses

Crystal Structures of Main Proteases of SARS-CoV-2 Variants Bound to a Benzothiazole-Based Inhibitor

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19

Exploring the Binding Mechanism of the Main Proteinase in SARS-associated Coronavirus and Its Implication to Anti-Sars Drug Design.

Progress of SARS-CoV-2 Main protease peptide-like inhibitors

A Novel Y-Shaped, S-O-N-O-S-Bridged Cross-Link Between Three Residues C22, C44, and K61 is Frequently Observed in the SARS-CoV-2 Main Protease.

Crystal Structure of SARS-CoV-2 Main Protease (mpro) Mutants in Complex with the Non-Covalent Inhibitor CCF0058981.

Structure-Based Design of Covalent SARS-CoV-2 Papain-like Protease Inhibitors